Abbie D Leino1, Michael P Dorsch2, Corey A Lester2. 1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI aleino@umich.edu. 2. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI.
Abstract
OBJECTIVE: To evaluate statin use in the U.S. before and after the 2015 American Diabetes Association position statement, which expanded statin therapy recommendations to include all adults 40-75 years old with diabetes. RESEARCH DESIGN AND METHODS: The National Health and Nutrition Examination Survey (NHANES) was used to obtain a representative sample. The difference-in-differences technique determined the impact of the recommendation on the proportion of people with diabetes for whom statin therapy was newly recommended. RESULTS: Among people with diabetes, the change in statin use in people without atherosclerotic cardiovascular disease (ASCVD) risk factors, controlling for change among people with ASCVD/risk factors, was 6.6% (P = 0.388). In the adjusted analysis, overt ASCVD, age, Black race, health insurance, a place for routine care, and total cholesterol were significantly associated with statin use (P < 0.05). CONCLUSIONS: The most recent change in statin recommendations had minimal impact on the proportion of patients receiving a statin.
OBJECTIVE: To evaluate statin use in the U.S. before and after the 2015 American Diabetes Association position statement, which expanded statin therapy recommendations to include all adults 40-75 years old with diabetes. RESEARCH DESIGN AND METHODS: The National Health and Nutrition Examination Survey (NHANES) was used to obtain a representative sample. The difference-in-differences technique determined the impact of the recommendation on the proportion of people with diabetes for whom statin therapy was newly recommended. RESULTS: Among people with diabetes, the change in statin use in people without atherosclerotic cardiovascular disease (ASCVD) risk factors, controlling for change among people with ASCVD/risk factors, was 6.6% (P = 0.388). In the adjusted analysis, overt ASCVD, age, Black race, health insurance, a place for routine care, and total cholesterol were significantly associated with statin use (P < 0.05). CONCLUSIONS: The most recent change in statin recommendations had minimal impact on the proportion of patients receiving a statin.
Authors: Maja E Marcus; Jennifer Manne-Goehler; Michaela Theilmann; Farshad Farzadfar; Sahar Saeedi Moghaddam; Mohammad Keykhaei; Amirali Hajebi; Scott Tschida; Julia M Lemp; Krishna K Aryal; Matthew Dunn; Corine Houehanou; Silver Bahendeka; Peter Rohloff; Rifat Atun; Till W Bärnighausen; Pascal Geldsetzer; Manuel Ramirez-Zea; Vineet Chopra; Michele Heisler; Justine I Davies; Mark D Huffman; Sebastian Vollmer; David Flood Journal: Lancet Glob Health Date: 2022-03 Impact factor: 26.763
Authors: Kiersten L Strombotne; Jessica Lum; Nambi J Ndugga; Anne E Utech; Steven D Pizer; Austin B Frakt; Paul R Conlin Journal: Diabetes Obes Metab Date: 2021-08-19 Impact factor: 6.577